# A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

> **NCT05677438** · PHASE2 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 121 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** CKD-498 dose#1
- **DRUG:** CKD-498 dose#2
- **DRUG:** CKD-498 dose#3
- **DRUG:** Placebo of CKD-498 dose#1
- **DRUG:** Placebo of CKD-498 dose#2
- **DRUG:** Placebo of CKD-498 dose#3

## Key facts

- **NCT ID:** NCT05677438
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-20
- **Primary completion:** 2023-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05677438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05677438, "A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05677438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*